Cytokinetics
CYTK
61.12
-0.23
-0.37%
Cytokinetics
US · CYTK
#1564 by market cap
Listed 1970
61.12
-0.23
-0.37%
Live - 5344 symbols - heartbeat 546s ago
· 2026-10-08 08:22
Pre-market
60.75
-0.61%
After-hours
61.12
0.00%
- Market cap
- 8.50B
- P/E (TTM)i
- -8.47
- P/Bi
- -48.97
- EPSi
- -6.54
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on CYTK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -1.74, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +376.56% YoY
Margins
- Operating margin
- -695.44%
- Net margin
- -891.60%
Key ratios & quality
- Enterprise valuei
- 8.79B
- Altman Z-Scorei
- -1.74
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 31.50M | 26.87M | 55.83M | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 31.28M | 39.61M | 52.82M | 96.80M | 177.98M | 173.61M | 215.31M | 284.27M |
| Research & development | 89.14M | 86.13M | 96.95M | 159.94M | 240.81M | 330.12M | 339.41M | 416.03M |
| Operating profit | -88.92M | -98.87M | -93.94M | -186.31M | -324.20M | -496.21M | -536.25M | -612.26M |
| Pretax profit | -106.29M | -121.69M | -127.29M | -215.31M | -388.96M | -526.24M | -589.53M | -784.96M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -106.29M | -121.69M | -127.29M | -215.31M | -388.96M | -526.24M | -589.53M | -784.96M |
| Basic EPS | -2 | -2 | -2 | -3 | -4 | -5 | -5 | -7 |
| Diluted EPS | -1.95 | -2.11 | -1.97 | -2.80 | -4.33 | -5.45 | -5.26 | -6.54 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.58M | 66.77M | 1.94M | 17.76M | 19.36M | 28.62M |
| Gross profit | 0 | 64.35M | -- | -- | 16.80M | 23.03M |
| Selling & admin expenses | 57.37M | 65.72M | 69.46M | 91.72M | 104.90M | 104.40M |
| Research & development | 98.26M | 110.14M | 99.23M | 104.40M | 95.53M | 97.81M |
| Operating profit | -155.63M | -111.51M | -166.76M | -178.37M | -183.62M | -179.17M |
| Pretax profit | -161.38M | -134.37M | -306.18M | -183.03M | -206.03M | -198.76M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -161.38M | -134.37M | -306.18M | -183.03M | -206.03M | -198.76M |
| Basic EPS | -1 | -1 | -3 | -2 | -2 | -2 |
| Diluted EPS | -1.36 | -1.12 | -2.55 | -1.50 | -1.67 | -1.50 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 207.67M | 233.75M | 474.22M | 535.67M | 795.19M | 628.05M | 1.11B | 916.98M |
| Cash & ST investments | 198.73M | 225.11M | 464.06M | 471.64M | 782.58M | 614.82M | 1.08B | 882.22M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 211.18M | 289.81M | 533.80M | 841.32M | 1.01B | 824.32M | 1.40B | 1.42B |
| Total current liabilities | 22.19M | 26.02M | 31.20M | 71.86M | 84.62M | 102.68M | 179.67M | 202.45M |
| Short-term debt | 2.61M | 4.62M | 2.79M | 14.86M | 13.79M | 27.97M | 30.50M | 60.29M |
| Long-term debt | 39.81M | 129.26M | 135.71M | 142.84M | 609.62M | 607.37M | 645.60M | 1.12B |
| Total liabilities | 185,244,000.00 | 300,751,000.00 | 420,420,000.00 | 597,456,000.00 | 1,122,675,000.00 | 1,210,639,000.00 | 1,537,045,000.00 | 2,084,162,000.00 |
| Total equity | 25.93M | -10.94M | 113.38M | 243.86M | -107.90M | -386.32M | -135.37M | -659.63M |
| Retained earnings | -743.32M | -865.02M | -992.31M | -1.21B | -1.59B | -2.11B | -2.70B | -3.49B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 956.05M | 886.54M | 977.35M | 916.98M | 839.47M | 1.21B |
| Cash & ST investments | 938.22M | 858.14M | 962.54M | 882.22M | 818.55M | 1.17B |
| Inventory | -- | -- | -- | -- | 154.00K | 380.00K |
| Total assets | 1.26B | 1.23B | 1.44B | 1.42B | 1.27B | 1.92B |
| Total current liabilities | 159.73M | 131.06M | 142.14M | 202.45M | 199.19M | 181.43M |
| Short-term debt | 32.53M | 33.99M | 37.93M | 60.29M | 65.77M | 48.40M |
| Long-term debt | 645.17M | 713.05M | 1.05B | 1.12B | 1.12B | 1.12B |
| Total liabilities | 1,530,464,000.00 | 1,594,355,000.00 | 1,957,680,000.00 | 2,084,162,000.00 | 2,100,046,000.00 | 2,098,038,000.00 |
| Total equity | -266.41M | -368.72M | -521.12M | -659.63M | -826.57M | -173.49M |
| Retained earnings | -2.86B | -3.00B | -3.30B | -3.49B | -3.69B | -3.89B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -101.22M | -90.91M | 8.94M | -142.52M | -299.52M | -414.33M | -395.89M | -510.01M |
| Depreciation & amortization | 1.24M | 1.29M | 1.83M | 2.28M | 5.81M | 11.89M | 9.53M | 10.13M |
| Free cash flow | -102.10M | -93.53M | -2.11M | -191.39M | -310.85M | -415.75M | -399.80M | -534.82M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 36.21M | 225.11M | 312.05M | 0 | 164.23M | 706.84M | 0 |
| Ending cash balance | 42.26M | 36.43M | 82.99M | 112.67M | 67.18M | 113.40M | 95.23M | 125.63M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -131.62M | -128.24M | -107.51M | -142.65M | -145.46M | -159.84M |
| Depreciation & amortization | 2.30M | 2.29M | 2.68M | 2.86M | 3.38M | 3.63M |
| Free cash flow | -137.28M | -132.38M | -116.86M | -148.30M | -151.39M | -164.17M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | -- | -- |
| Ending cash balance | 74.06M | 76.55M | 228.58M | 125.63M | 132.95M | 258.38M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -156.57 | -1,622.88 | -248.50 | -120.54 | -572.15 | -- | -- | -- |
| ROA %i | -42.01 | -48.58 | -30.91 | -31.32 | -41.91 | -57.23 | -52.97 | -55.55 |
| ROIC %i | -83.66 | -102.20 | -49.78 | -48.64 | -60.45 | -- | -- | -- |
| 5-year avg ROE %i | -65.64 | -386.22 | -426.58 | -454.73 | -544.13 | -- | -- | -- |
| EBIT margin %i | -268.96 | -351.09 | -158.73 | -264.07 | -357.13 | -6,222.79 | -2,722.82 | -773.62 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 9.36 | 8.98 | 15.20 | 7.45 | 9.40 | 6.12 | 6.17 | 4.53 |
| Quick ratioi | 9.26 | 8.85 | 15.02 | 7.28 | 9.25 | 6.00 | 6.08 | 4.45 |
| Debt / assetsi | 20.45 | 46.95 | 26.03 | 32.08 | 73.94 | 91.68 | 56.27 | 90.15 |
| LT debt / equityi | 156.46 | -- | 120.08 | 104.59 | -- | -- | -- | -- |
| Interest coveragei | -3.93 | -3.45 | -2.29 | -6.34 | -6.60 | -8.13 | -5.81 | -6.56 |
| Revenue CAGR (3Y) %i | 3.20 | -36.79 | 61.04 | 30.76 | 52.12 | -48.72 | -35.99 | -2.36 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -59.38 | -44.10 | -52.35 | -55.55 | -65.39 | -56.76 |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -2,722.04 | -599.74 | -751.99 | -773.62 | -676.04 | -1,136.66 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.99 | 6.76 | 6.88 | 4.53 | 4.21 | 6.66 |
| Quick ratioi | 5.89 | 6.61 | 6.78 | 4.45 | 4.14 | 6.56 |
| Debt / assetsi | 62.58 | 70.01 | 83.31 | 90.15 | 101.20 | 66.02 |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -5.68 | -5.58 | -6.82 | -6.56 | -6.26 | -6.16 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 08:22:52 · For reference only, not investment advice and not tailored to your situation.